

Myobloc® (rimabotulinumtoxinB)

When requesting Myobloc® (rimabotulinumtoxinB), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial use and meet the specific coverage guidelines for the covered indications.

FDA-Approved Indications

- Treatment of cervical dystonia in adults.
- Treatment of chronic sialorrhea in adults.

Approved Off-label Compendial Use

- Upper limb spasticity

Coverage Guidelines

The individual must be 18 years of age or older for approval of the following indications:

- Cervical dystonia (Spasmodic torticollis)
- Chronic sialorrhea
- Upper limb spasticity

Approval duration: 12 months

Dosing Recommendations

Cervical Dystonia

The recommended dosage is 2,500 units to 5,000 units divided among affected muscles, administered no more frequently than every 12 weeks.

Chronic Sialorrhea

The recommended dosage is 1,500 units to 3,500 units, divided among the parotid and submandibular glands, administered no more frequently than every 12 weeks.

Upper Limb Spasticity

The recommended dosage is 20,000 units, administered no more frequently than every 12 weeks.

References

1. Myobloc® injection [prescribing information]. San Francisco, CA: Solstice Neurosciences; December 2023.
2. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016;86:1818-1826.
3. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. *Clin Aesthet Dermatol*. 2014;7(21):31-39.
4. Botox® injection [prescribing information]. Madison, NJ: Allergan; November 2023.